Viagra Therapy and IVF: The Role of Uterine Receptivity in Outcome
702-892-9696
Fax:
702-892-9666
The considerable emotional, physical and financial burden associated with infertility treatment in general and with IVF in specific, demand that factors known to affect outcome be identified and regulated prior to initiating treatment. In this post, I’ll address the influence of factors that affect uterine/endometrial receptivity to embryo implantation and discuss approaches to treatment.
1. Contour of the uterine cavity
It has long been suspected that anatomical defects of the uterus might result in infertility.
While the presence of myomas (fibroids) in the uterine wall are unlikely to cause infertility, an association between their presence and infertility has been observed in cases where they distort the uterine cavity, or protrude as submucous polyps through the endometrial lining. It would appear that even small submucous myomas have the potential to prejudice implantation.
It is likely that any surface lesion in the uterine cavity, whether an endometrial, placental or fibroid polyp (no matter how small), or intrauterine adhesions, has the potential to interfere with implantation by producing a local inflammatory response, not too dissimilar in nature from that which is caused by a foreign body such as a intrauterine contraceptive device. Unfortunately, a dye X-Ray test (hysterosalpingogram or HSG) will miss the diagnosis in approximately 20% of cases. The only reliable methods for diagnosing even the smallest of such lesions is through the performance of a sonohysterogram (SHG), or by hysteroscopy.
Sonohysterography (SHG): A sonohysterogram (also known as a Fluid Ultrasound [FUS]) is a procedure whereby a sterile solution of saline is injected via a catheter through the cervix and into the uterine cavity. The fluid-distended cavity is then examined by vaginal ultrasound for any irregularities that might point to surface lesions such as polyps, fibroid tumors, scarring, or a uterine septum. If performed by an expert, SHG is highly effective in recognizing even the smallest surface lesions that protrude into the uterine cavity. SHG is less expensive, less traumatic, and equally diagnostically reliable as hysteroscopy. The only disadvantage lies in the fact that if a lesion is detected, it may require the subsequent performance of hysteroscopy to treat the problem anyway.
Hysteroscopy: Diagnostic hysteroscopy is an office procedure that is performed under intravenous sedation, general or local anesthesia, with minimal discomfort to the patient. The procedure involves the insertion of a thin, lighted, telescope‑like instrument known as a hysteroscope through the vagina and cervix into the uterus in order to fully examine the uterine cavity. The uterus is first distended with carbon dioxide gas, which is passed through a sleeve adjacent to the hysteroscope. As is the case with FUS, diagnostic hysteroscopy facilitates examination of the inside of the uterus under direct vision for defects that might interfere with implantation.
We have observed that approximately one in eight candidates for IVF have intrauterine lesions that require attention prior to undergoing IVF in order to optimize the chances of a successful outcome. We strongly recommend that all patients who have such lesions undergo therapeutic surgery (usually via hysteroscopic resection) to correct the pathology prior to undergoing IVF. Depending on the severity and nature of the pathology, therapeutic hysteroscopy may require general anesthesia. If so, it should be performed in an outpatient surgical facility or in a conventional operating room.
2. Endometrial Thickness
In 1989, we were first to show that in both normal and “stimulated” cycles, preovulatory endometrial thickness as assessed by ultrasound examination, is predictive of embryo implantation (pregnancy) potential following IVF. Ideally, the endometrium should measure at least 9.0mm in thickness. However, although much less likely, healthy pregnancies can occur with linings that measure between 7.5 and 9.0mm
A “poor” endometrial lining is most commonly due to: 1) inflammation of the uterine lining (endometritis) that usually occurs as a result of a septic delivery, abortion or miscarriage, 2) severe adenomyosis (gross invasion of the uterine muscle by endometrial glandular tissue), 3) multiple fibroid tumors of the uterine wall) 4) prenatal exposure to the synthetic hormone, diethylstilbestrol (DES) and, 5) following back to back cycles of clomiphene citrate ovulation induction.
Treatment with vaginal Viagra: Hitherto, attempts to augment endometrial growth in women with poor endometrial linings by bolstering circulating estrogen blood levels (through the administration of increased doses of fertility drugs, aspirin administration and by supplementary estrogen therapy) have yielded disappointing results.
We recently demonstrated that the vaginal administration of sildenafil (Viagra) for several days prior to the “hCG trigger “ or progesterone administration enhances uterine blood flow and estrogen delivery to the uterine lining, and so improves endometrial thickening.
In October 2002, we reported on the administration of vaginal Viagra to 105 women with repeated IVF failure due to persistently thin endometrial linings. All of the women had experienced at least two (2) prior IVF failures attributed to intractably thin uterine linings. About 70% of these women responded to treatment with Viagra suppositories with a marked improvement in endometrial thickness and 45% of these achieved live IVF- births following a single cycle of treatment with Viagra. 9% miscarried. None of the women who had failed to achieve an improvement in endometrial thickness following Viagra and who subsequently underwent embryo transfers achieved viable pregnancies.
Since the introduction of this form of treatment, more than 500 women have been reported treated and many have gone on to have babies after repeated prior IVF failure.
3. Immunologic Factors
The implantation process of the embryo in the uterus begins six or seven days after fertilization of the egg. At this time, specialized embryonic cells (i.e., the trophoblast), which later becomes the placenta, begin growing into the uterine lining. When the trophoblast and the uterine lining meet, they, along with Immune cells in the lining, become involved in a “cross talk” through mutual exchange of hormone-like substances called cytokines. Because of this complex immunologic interplay, the uterus is able to foster the embryo’s successful growth. Thus, from the very earliest stage of implantation the trophoblast establishes a foundation for the future nutritional, hormonal and respiratory interchange between mother and baby. In this manner, the interactive process of implantation is not only central to survival in early pregnancy but also to the quality of life after birth.
Considering its importance, it is not surprising that problems with this immunologic interaction during implantation have been implicated as a cause of recurrent miscarriage, late pregnancy fetal loss, IVF failure, and infertility. A partial list of immunologic factors that may be involved in these situations includes anti-phospholipid antibodies (APA), antithyroid antibodies (ATA), and, perhaps most importantly, activated natural killer cells (NKa). Presently, these immunologic markers in the blood can be adequately measured by only a few (less than a half dozen) highly specialized reproductive immunology laboratories in the United States.
The Central Role of Natural Killer Cells: After ovulation and during early pregnancy, NK cells comprise more than 70% of the immune cell population of the uterine lining. NK cells produce a variety of local hormones known as TH-1 cytokines. Uncontrolled, excessive release of TH-1 cytokines is highly toxic to the trophoblast and endometrial cells, leading to their programmed death (apoptosis) and, subsequently to failed implantation. In the following situations, NK cells become activated and start to produce an excess of TH-1 cytokines: 1) Aloimmune implantation dysfunction where the male and female partners share specific genetic (DQ-alpha and/or HLA) similarities and 2) in Autoimmune conditions such as Rheumatoid arthritis, hypothyroidism endometriosis and Lupus Erythematosis.
Activated NK cells (NKa) can be detected in peripheral blood where their toxicity can be measured. Intralipid (IL) therapy, initiated more than 1week prior to embryo transfer, can subdue activated NK cells, thereby reducing the risk of implantation failure.
7 Responses to “Viagra Therapy and IVF: The Role of Uterine Receptivity in Outcome”
Leave a Reply
Top Search Terms for In Vitro Fertilization
- Embryo Quality & Embryo “Competence” – Part III – Testing the Seed
- Embryo Quality & Embryo “Competence” – Part One: Planting a Good Seed
- The Needle vs. the Dish: Should ICSI Be Used in All IVF?
- Embryo Implantation: What Farmers Can Teach us About Growing Healthy Babies
- Acupuncture and IVF: Does it Improve Success?
Ask Our DoctorsA Question












Dr Sher, you mentioned about lining being too thin for implantation and about 9mm is optimal. Could you comment on lining being too thick such as 19mm which I had on my last IVF cycle? Is that fine for embryo implantation? I am not sure why my lining was that thick.
In the past sonographers have commented that my lining at CD2/3 is thicker than normal range, so they concluded that that's just me. And my doctor who did a hysteroscopy on me before I commenced on IVF said everything looked good except a tiny polyp which he removed. I do not have endometriosis or fibriods or any other problem, just thick lining but yet really short periods about 1.5 to 2.5 days. It is puzzling.
I am 37. We have a 6YO son naturally but are having secondary infertility with DH having low sperm numbers and poor morphology and motility and my ovarian reserve is on the lower side. Our recent IVF Down Reg with Agonist + ICSI-HA did not achieve pregnancy. Thank you for your comment/advice.
I have had two failed donor egg cycles in Los Angeles, CA. One with a fresh embryo, 5 day blastocyst B Class) and the other with a frozen embryo 5 day blastocyst, this time with 2 embryos implanted (B Class). Neither worked. On the second occaision even with taking a lot of Oestrogen (Estrace I think) and with an Oestrogen blood count of 5,000 i still only had a 7mm lining after 2 weeks of taking the medications. Finally the endometrium got up to 9mm and they think trilaminar but it didn’t work. I have decided to have a Hysteroscopy even though I have already had a 3D Aquascan (HSS test) in the UK. But after taking 2mg of Oestrogen twice a day (Progynova) to thicken the lining (I did not have my period for 48 days and had a lining of 5.9mm) they put me on Oestrogen in the UK at The Bridge Centre to build up my lining for the Hysteroscopy but after being on the pills for a week I had break through bleeding 2 days ago and my lining is now down to 2.8mm. They are saying that I have an “unstable endometrium” that it is not a period but rather “breakthrough bleeding” they are taking blood tests and will probably advise more oestrogen to try to build up a lining before the Hysteroscopy but have advised that your method of Viagra (although apparently it must be compound Viagra not available in the Uk) might help blood flow to help my endometrium work??? They told me there was a blog to ask you about it. I could not find the blog so I am leaving a question here. I live in London, England but also visit Los Angeles a fair bit where my frozen donor embryo is. What would you advise. My doctor in Beverly Hills, is Dr Hal Danzer of the SCRC and my doctor in the UK is Mr Michael Summers of The Bridge Centre, London. If my endometrium is not responding for inplantation or even for a Hysteroscopy what is the likelihood of it holding a pregnancy and would valium help? If you think it would, would I be able to get the compound version shipped to my doctor in the UK? Here the valium they have are regular pills. Or does this mean I need a surrogate??!! Thank you Sharon my email is: newhorizonpics@aol.com or my tel number in the UK (8 hours ahead of Los Angeles time zone) is 011 44 779 247 6996.
Please go to my blog posted on this site on September, 3rd 2009, entitled “Viagra Therapy and IVF: The Role of Uterine Receptivity in Outcome”. Hopefully you will find it to be helpful.
Geoff Sher
I’m very interested to read about NK issues and ratio of problems for those with endometriosis and Hashimotos. What is the likelyhood that immunity is issue for donor-egg conception/success when one has been diagnosed with both?
The same as when own eggs are used.;
Geoff Sher
800-780-7437
I’m 36, and have gone through two fresh IVF cycles with PGD since 2009 because my husband and I are carriers of cystic fibrosis. I also have pcos, though I do not exhibit weight problems or hair loss.
Our history is as follows: fresh cycle (42 eggs) and transfer (2 embryos), miscarriage at ten weeks; fet (2 embryos), daughter in 2010, vanishing twin; fet (1 embryo), failure. Second fresh cycle (only embryo due to OHSS), failure; fet (2 embryos), failure; fet (2 embryos), miscarriage/chemical pregnancy. We have one frozen embryo left, but the embryo is of poor quality.
We did more blood testing to check thyroid levels and the like to determine possible cause for the three miscarriages, and my levels were incredibly normal. However, there was a presence of anti thyroid antibodies, suggesting hashimoto’s. is there any kind of treatment for this? Any hope? I was given some Synthroid, but it seems that treats my TSH level, which is 1.5. I’m having difficulty finding information about other people with these kind of stats.
It certainly sounds like an immune implantation issue.I think I can help you. The cystic fibrosis carrier state is something separate.
Please go to the home page of this blog, http://www.IVFauthority.com. When you get there, look for a “search bar” in the upper right hand corner. Type the following subjects into the bar, click on it and it will take you to all the relevant articles posted there.
1. “An Individualized Approach to Ovarian stimulation” (posted on November 22nd, 2010)
2. “Ovarian Stimulation in IVF: Why is it important to down-regulate LH?”
3. “Agonist/Antagonist Conversion Protocol”
4. “Immunologic Implantation Dysfunction” (posted on May, 10th and on May 16th respectively.
5. “Embryo Implantation………” (Part-1 and Part- 2—-Posted August 2012)
6. “Recurrent Pregnancy Loss (RPL)!
7.“A personalized, stepwise approach to IVF at SIRM”; Parts 1 & 2 (posted March, 2012)
8. “IVF success: Factors that influence outcome”
Consider calling 800-780-7437 or 702-699-7437 to arrange a Skype consultation (free of charge to those who reside in the United States or Canada) with me so we can discuss your case in detail
Geoff Sher